KR102619415B1 - 안드로겐 박탈 요법 연관 증상의 치료 - Google Patents

안드로겐 박탈 요법 연관 증상의 치료 Download PDF

Info

Publication number
KR102619415B1
KR102619415B1 KR1020227032523A KR20227032523A KR102619415B1 KR 102619415 B1 KR102619415 B1 KR 102619415B1 KR 1020227032523 A KR1020227032523 A KR 1020227032523A KR 20227032523 A KR20227032523 A KR 20227032523A KR 102619415 B1 KR102619415 B1 KR 102619415B1
Authority
KR
South Korea
Prior art keywords
day
dose
compound
treatment
males
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227032523A
Other languages
English (en)
Korean (ko)
Other versions
KR20220132669A (ko
Inventor
한나 유
레이첼 리치
찰스 토마스 벤슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20220132669A publication Critical patent/KR20220132669A/ko
Application granted granted Critical
Publication of KR102619415B1 publication Critical patent/KR102619415B1/ko
Assigned to 옵코 헬스, 인크. reassignment 옵코 헬스, 인크. 권리의 전부이전등록 Assignors: 일라이 릴리 앤드 캄파니
Assigned to 에어젠 파마 엘티디. reassignment 에어젠 파마 엘티디. 권리의 전부이전등록 Assignors: 옵코 헬스, 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
KR1020227032523A 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료 Active KR102619415B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11
US62/049,192 2014-09-11
PCT/US2015/048801 WO2016040234A1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms
KR1020217019807A KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019807A Division KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Publications (2)

Publication Number Publication Date
KR20220132669A KR20220132669A (ko) 2022-09-30
KR102619415B1 true KR102619415B1 (ko) 2024-01-02

Family

ID=54151401

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227032523A Active KR102619415B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020187010670A Active KR102024493B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020217019807A Ceased KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020197003498A Ceased KR20190015628A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020177006425A Ceased KR20170040338A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187010670A Active KR102024493B1 (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020217019807A Ceased KR20210083370A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020197003498A Ceased KR20190015628A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료
KR1020177006425A Ceased KR20170040338A (ko) 2014-09-11 2015-09-08 안드로겐 박탈 요법 연관 증상의 치료

Country Status (23)

Country Link
US (4) US10758515B2 (https=)
EP (2) EP3191094B1 (https=)
JP (4) JP6893171B2 (https=)
KR (5) KR102619415B1 (https=)
CN (4) CN106794178A (https=)
AP (1) AP2017009795A0 (https=)
AU (2) AU2015315431C1 (https=)
BR (2) BR112017002449B1 (https=)
CA (2) CA2956514C (https=)
EA (2) EA034553B1 (https=)
ES (1) ES2779978T3 (https=)
HK (1) HK1252811A1 (https=)
IL (3) IL279209B2 (https=)
JO (2) JOP20180072A1 (https=)
MA (1) MA45416A (https=)
MX (3) MX373322B (https=)
MY (2) MY198753A (https=)
NZ (1) NZ728612A (https=)
SG (2) SG11201701630VA (https=)
TW (1) TWI616201B (https=)
UA (1) UA120099C2 (https=)
WO (1) WO2016040234A1 (https=)
ZA (1) ZA201802680B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4603528B2 (ja) * 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
KR20090012342A (ko) 2006-05-31 2009-02-03 글락소 그룹 리미티드 신규한 헤테로시클릭 화합물
BRPI0713198A2 (pt) * 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
EP2222636B1 (en) * 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
EA019713B1 (ru) * 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
CN104870422B (zh) 2012-10-31 2019-03-15 富士胶片富山化学株式会社 胺衍生物或其盐
BR112016012243A2 (pt) * 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drug Metabolism & Disposition (20121231), 40(12), pp. 2354-2364
Endocrinology vol. 146, no. 11, pp. 4887-4897(2005. 11. 01.)

Also Published As

Publication number Publication date
SG10201809673RA (en) 2018-12-28
EP3191094B1 (en) 2020-02-19
EA201891008A2 (ru) 2018-09-28
CA3067289C (en) 2023-04-04
AU2018202714A1 (en) 2018-05-17
KR102024493B1 (ko) 2019-09-23
MX373322B (es) 2020-05-21
JP2019089795A (ja) 2019-06-13
US10758515B2 (en) 2020-09-01
EA201891008A3 (ru) 2019-03-29
MX2021014120A (es) 2022-01-04
EP3191094A1 (en) 2017-07-19
AU2015315431B2 (en) 2018-03-08
US20240148694A1 (en) 2024-05-09
AU2018202714B2 (en) 2019-06-20
JO3609B1 (ar) 2020-08-27
CA2956514C (en) 2023-04-18
NZ728612A (en) 2018-03-23
IL279209B (en) 2022-10-01
BR122018007412B1 (pt) 2022-08-23
MA45416A (fr) 2019-04-24
KR20170040338A (ko) 2017-04-12
MY195767A (en) 2023-02-10
EA033606B1 (ru) 2019-11-08
EA201790220A1 (ru) 2017-07-31
JP2017527584A (ja) 2017-09-21
JOP20180072A1 (ar) 2019-01-30
KR20220132669A (ko) 2022-09-30
AU2015315431C1 (en) 2018-08-02
JP6893171B2 (ja) 2021-06-23
CA2956514A1 (en) 2016-03-17
KR20180041268A (ko) 2018-04-23
US10799478B2 (en) 2020-10-13
KR20190015628A (ko) 2019-02-13
CA3067289A1 (en) 2016-03-17
ZA201802680B (en) 2020-08-26
CN113651797A (zh) 2021-11-16
IL258651B (en) 2021-02-28
ES2779978T3 (es) 2020-08-21
TWI616201B (zh) 2018-03-01
IL250291A0 (en) 2017-03-30
JP6938550B2 (ja) 2021-09-22
KR20210083370A (ko) 2021-07-06
IL258651A (en) 2018-06-28
JP2023145479A (ja) 2023-10-11
HK1252811A1 (en) 2019-06-06
CN113521068A (zh) 2021-10-22
MY198753A (en) 2023-09-23
MX391447B (es) 2025-03-21
US20200390744A1 (en) 2020-12-17
IL250291B (en) 2020-09-30
CN108440497A (zh) 2018-08-24
BR112017002449A2 (pt) 2017-12-05
IL279209B2 (en) 2023-02-01
AU2015315431A1 (en) 2017-03-09
JP2022000432A (ja) 2022-01-04
UA120099C2 (uk) 2019-10-10
TW201618782A (zh) 2016-06-01
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
EA034553B1 (ru) 2020-02-19
US20190111039A1 (en) 2019-04-18
AP2017009795A0 (en) 2017-03-31
US20170172992A1 (en) 2017-06-22
MX2017003140A (es) 2017-05-23
WO2016040234A1 (en) 2016-03-17
JP7349480B2 (ja) 2023-09-22
CN106794178A (zh) 2017-05-31
EP3375444A1 (en) 2018-09-19
SG11201701630VA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
US20240148694A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508B (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301